EA201071326A1 - Новые противоопухолевые конъюгаты двойного действия - Google Patents

Новые противоопухолевые конъюгаты двойного действия

Info

Publication number
EA201071326A1
EA201071326A1 EA201071326A EA201071326A EA201071326A1 EA 201071326 A1 EA201071326 A1 EA 201071326A1 EA 201071326 A EA201071326 A EA 201071326A EA 201071326 A EA201071326 A EA 201071326A EA 201071326 A1 EA201071326 A1 EA 201071326A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tumor
double action
compounds
new anti
conjugates
Prior art date
Application number
EA201071326A
Other languages
English (en)
Russian (ru)
Inventor
Альма Даль Поццо
Эмильяно Эспозито
Минхун Ни
Серджо Пенко
Клаудио Пизано
Массимо Касторина
Лоредана Веши
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201071326A1 publication Critical patent/EA201071326A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA201071326A 2008-05-20 2009-05-11 Новые противоопухолевые конъюгаты двойного действия EA201071326A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08156575 2008-05-20
PCT/EP2009/055653 WO2009141240A1 (en) 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates

Publications (1)

Publication Number Publication Date
EA201071326A1 true EA201071326A1 (ru) 2011-06-30

Family

ID=39765065

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071326A EA201071326A1 (ru) 2008-05-20 2009-05-11 Новые противоопухолевые конъюгаты двойного действия

Country Status (16)

Country Link
US (1) US20110160147A1 (https=)
EP (1) EP2285396A1 (https=)
JP (1) JP2011523415A (https=)
KR (1) KR20110022594A (https=)
CN (1) CN102036676A (https=)
AR (1) AR071840A1 (https=)
AU (1) AU2009249795A1 (https=)
BR (1) BRPI0911978A2 (https=)
CA (1) CA2724562A1 (https=)
EA (1) EA201071326A1 (https=)
IL (1) IL208920A0 (https=)
MX (1) MX2010012320A (https=)
NZ (1) NZ588948A (https=)
TW (1) TW201004647A (https=)
WO (1) WO2009141240A1 (https=)
ZA (1) ZA201009036B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
EA031930B1 (ru) 2013-01-30 2019-03-29 Авелас Байосайенсиз, Инк. Молекула селективной доставки для визуализации злокачественной ткани
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10125124B2 (en) 2015-03-20 2018-11-13 Massachusetts Institute Of Technology Formation of macromolecules using iterative growth and related compounds
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
EA202191244A1 (ru) * 2018-11-05 2021-10-11 Байер Фарма Акциенгезельшафт Новые цитостатические конъюгаты с лигандами интегрина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US8404650B2 (en) * 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof

Also Published As

Publication number Publication date
TW201004647A (en) 2010-02-01
CN102036676A (zh) 2011-04-27
JP2011523415A (ja) 2011-08-11
MX2010012320A (es) 2010-12-01
NZ588948A (en) 2011-10-28
ZA201009036B (en) 2012-01-25
IL208920A0 (en) 2011-01-31
AU2009249795A1 (en) 2009-11-26
WO2009141240A1 (en) 2009-11-26
KR20110022594A (ko) 2011-03-07
US20110160147A1 (en) 2011-06-30
EP2285396A1 (en) 2011-02-23
BRPI0911978A2 (pt) 2019-09-24
AR071840A1 (es) 2010-07-21
CA2724562A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
EA201071326A1 (ru) Новые противоопухолевые конъюгаты двойного действия
EA200971013A1 (ru) Соединения-антагонисты рнк для модуляции активности бета-катенина
BR112012016376A2 (pt) compostos de pirrolo-aminopirimida substituída
ATE491020T1 (de) Lösungsmitteltolerante mikroorganismen und isolationsverfahren
CY1116311T1 (el) Συνθεσεις ινσουλινων υπερ-ταχειας δρασης
BRPI0923786C1 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112013016929A2 (pt) oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
BR112015013129A2 (pt) métodos e materiais para a biossíntese de compostos mogrosida
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
BR112014012129A2 (pt) inibidores heterocíclicos de glutaminase
EP2668296A2 (en) Colon cancer gene expression signatures and methods of use
WO2012037155A3 (en) Tyrosine kinase inhibitors
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
BR112012029280A2 (pt) variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2010025872A3 (en) Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl
AU2012328921A8 (en) Immunobinders directed against TNF
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
IN2012MN02262A (https=)